The Global CMT Research Convention brings together the full spectrum of the Charcot-Marie-Tooth ecosystem in one place: leading scientists, biotech and pharma companies, investors, regulatory agencies and patients, all focused on accelerating treatments for the most common inherited peripheral neuropathy in the world.
The 2026 Convention will be held September 24–26, 2026 in Cambridge, MA, and registration is currently open with early bird rates through June 30th.
The convention programming for Thursday and Friday offers a rare opportunity to engage directly with the researchers shaping the CMT pipeline, identify collaboration and investment opportunities, and gain a ground-level view of where the field is headed.
-
- Thursday features cutting-edge learnings in CMT research, including new biological discoveries as well as advances in genetic and genomic technologies.
-
- Don’t miss Friday’s keynote from Dr. Anna Greka, the founder of the Ladders to Cures (L2C) Scientific Accelerator at the Broad Institute of MIT and Harvard.
-
- Saturday features programming for patients, creating unique opportunities for interaction, including recruitment through the convention’s Clinical Trial Fair.
Important scientific topics discussed will include:
-
- Clinical Trial Endpoints for CMT Drug Development
-
- Engaging Venture Capital to Accelerate Research
-
- Advances in Genetic and Genomic Technologies in CMT
-
- Collaboration Opportunities across Rare Diseases
As we get closer, we will continue to unveil new speakers, topics and opportunities to expect at the convention.
With more active drug trials in CMT than ever before, the timing has never been better to get in the room.
